(Q38973284)

8 September 2017

miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin (English)

1 reference

8 September 2017

1 reference

9

1 reference

8 September 2017

10

Frank Speleman

1 reference

8 September 2017

Kwanghee Baek

14

0 references

Pieter Mestdagh

Pieter Mestdagh

4

0 references

Johannes H Schulte

Johannes H Schulte

18

0 references

Angelika Eggert

Angelika Eggert

16

0 references

Matthias Epple

Matthias Epple

11

0 references

Jo Vandesompele

Jo Vandesompele

15

0 references

author name string

Kristina Althoff

1

1 reference

8 September 2017

Sven Lindner

2

1 reference

8 September 2017

Andrea Odersky

3

1 reference

8 September 2017

Anneleen Beckers

5

1 reference

8 September 2017

Sarah Karczewski

6

1 reference

8 September 2017

Jan J Molenaar

7

1 reference

8 September 2017

Anna Bohrer

8

1 reference

8 September 2017

Diana Kozlova

12

1 reference

8 September 2017

Sena Yoon

13

1 reference

8 September 2017

Alexander Schramm

17

1 reference

8 September 2017

language of work or name

English

0 references

publication date

5 August 2014

1 reference

International Journal of Cancer

8 September 2017

13

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

8 September 2017

136

1 reference

8 September 2017

6

1 reference

8 September 2017

1308-1320

1 reference

8 September 2017

1 reference

Neuroblastoma: biology and molecular and chromosomal pathology

21 January 2018

1 reference

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

21 January 2018

1 reference

Long-term outcomes in patients with stage IV neuroblastoma

21 January 2018

1 reference

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

Chromosome 1p and 11q deletions and outcome in neuroblastoma

21 January 2018

1 reference

[Amplification of N-myc in neuroblastoma: paradigm for clinical use of an oncogene alteration]

21 January 2018

1 reference

Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas

21 January 2018

1 reference

The MYCN oncogene and differentiation in neuroblastoma

21 January 2018

1 reference

Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature

21 January 2018

1 reference

Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome.

21 January 2018

1 reference

Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe

21 January 2018

1 reference

MicroRNAs in the pathogenesis of neuroblastoma.

21 January 2018

1 reference

Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway.

21 January 2018

1 reference

MicroRNAs: target recognition and regulatory functions

21 January 2018

1 reference

MicroRNA function in cancer: oncogene or a tumor suppressor?

21 January 2018

1 reference

21 January 2018

1 reference

A microRNA polycistron as a potential human oncogene

21 January 2018

1 reference

The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma

21 January 2018

1 reference

c-Myc-regulated microRNAs modulate E2F1 expression

21 January 2018

1 reference

Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma

21 January 2018

1 reference

MYCN regulates oncogenic MicroRNAs in neuroblastoma

21 January 2018

1 reference

MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.

21 January 2018

1 reference

Accurate prediction of neuroblastoma outcome based on miRNA expression profiles

21 January 2018

1 reference

miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples

21 January 2018

1 reference

MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma

21 January 2018

1 reference

Induction of growth arrest by miR-542-3p that targets survivin.

21 January 2018

1 reference

Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles

21 January 2018

1 reference

The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation

21 January 2018

1 reference

MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.

21 January 2018

1 reference

Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma

21 January 2018

1 reference

Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome

21 January 2018

1 reference

Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis

21 January 2018

1 reference

A microRNA component of the p53 tumour suppressor network

21 January 2018

1 reference

A microRNA DNA methylation signature for human cancer metastasis

21 January 2018

1 reference

Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

21 January 2018

1 reference

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

21 January 2018

1 reference

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

21 January 2018

1 reference

DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2.

21 January 2018

1 reference

Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors

21 January 2018

1 reference

Chromosomal passengers and the (aurora) ABCs of mitosis

21 January 2018

1 reference

Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells

21 January 2018

1 reference

Aurora B kinase activation requires survivin priming phosphorylation by PLK1.

21 January 2018

1 reference

Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression

21 January 2018

1 reference

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

21 January 2018

1 reference

Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models

21 January 2018

1 reference

The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29091

1 reference

8 September 2017

1 reference